Zentalis to present preclinical azenosertib data at ESMO

Zentalis Pharmaceuticals announced that the company will present preclinical data from its selective WEE1 inhibitor azenosertib at the European Society of Medical Oncology 2024 Congress, occurring September 13-17 in Barcelona, Spain. Data in the abstract showed that the combination of azenosertib with TOP1 inhibitors demonstrated significant synergistic effects in all cell lines tested. In HER2+ breast cancer animal models, those treated with the combination of azenosertib plus trastuzumab deruxtecan resulted in 50% of animals showing complete tumor regression, compared with no CRs in monotherapy arms. Significant combination effects were also observed in a HER2+ ovarian model and a HER2-low breast cancer model. These data suggest that azenosertib significantly improves the anti-tumor effect of TOP1 inhibitors as well as ADCs with TOP1 inhibitor payload and that the combination could be a generalizable therapeutic approach for improving responses to ADCs in patients with advanced solid tumors.